Cipla Q1 FY27: net profit down 39% to ₹789 crore, revenue up 2%
Cipla (CIPLA) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹7,119 crore (+2.3% year on year), net profit of ₹789 crore (−39.2%), earnings per share of ₹9.77. The company is valued at about ₹1.08 lakh crore.
What happened
In a filing with the BSE on 27 October 2026 at 01:22 PM, Cipla (CIPLA) said that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹7,119 crore (+2.3% year on year), net profit of ₹789 crore (−39.2%), earnings per share of ₹9.77.
Company snapshot
Cipla is a large-cap company in the Healthcare sector, with a market value of about ₹1.08 lakh crore.
The stock last traded at ₹1,336.1, against a 52-week range of ₹1,165.7–₹1,593.8 (16.2% below the high).
Before this filing the shares had moved −3.3% over the month and −5.2% over three months. Average daily turnover over the last 20 sessions was about ₹132 crore.
Promoters held 29.21% at the end of Q1 FY27. Foreign institutions owned 20.21% and domestic institutions 34.63%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,957 | 1,297.6 | 16.07 |
| Q2 FY26 | 7,589 | 1,351.2 | 16.73 |
| Q3 FY26 | 7,074 | 675.8 | 8.37 |
| Q4 FY26 | 6,541 | 554.6 | 6.87 |
| Q1 FY27 | 7,119 | 789.1 | 9.77 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.7% over five days; 56% of them rose the next day.
Market-wide, 9,766 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 27 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- India's Cipla misses second-quarter profit view on muted US sales
- Cipla Q2 Preview: Net Profit Seen Falling 29% As US Business Faces Headwinds
- Weekly Recap: Cipla Ltd below 200‑week EMA and MF holdings up 2.6%
- Gaurav Kaul Takes Charge as Managing Director & CEO of Cipla Health Ltd
- Market wrap: Bajaj Finance, Cipla, Nestle India, Eternal top gainers and losers on Nifty and Sensex on Thu
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.